Please try another search
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Gorjan Hrustanovic | 35 | 2018 | Independent Director |
Frank P. McCormick | 74 | 2014 | Chairman of Scientific Advisory Board |
Sandra J. Horning | 75 | 2020 | Independent Director |
Sean W. Fanning | - | - | Member of Scientific Advisory Board |
Mark Sliwkowski | - | - | Member of Scientific Advisory Board |
Christopher C. Benz | - | - | Member of Scientific Advisory Board |
Cynthia Marie Butitta | 70 | 2020 | Independent Director |
Yi Larson | 43 | 2021 | Independent Director |
Pamela M. Klein | 63 | 2020 | Member of Scientific Advisory Board |
Cyrus L. Harmon | 53 | 2006 | Director |
Andrew S. Rappaport | 65 | 2013 | Independent Director |
Sean P. Bohen | 57 | 2020 | President, CEO & Director |
Graham Gordon Walmsley | 37 | 2020 | Independent Director |
Ian T. Clark | 64 | 2020 | Independent Chairperson of the Board |
Pamela Munster | - | - | Member of Scientific Advisory Board |
Jeffrey Hager | 59 | - | Member of Scientific Advisory Board |
Geoffrey Greene | - | - | Member of Scientific Advisory Board |
Scott Garland | 55 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review